Scancell Holdings Plc: LON:SCLP historical prices - Google FinanceScancell Holdings plc is a biopharmaceutical company focussed on the cancer therapeutics market. It is developing a pipeline of deoxyribonucleic acid (DNA) vacancies for the treatment of cancer based on its ImmunoBody platform. The Company is principally engaged in the business of discovery and development of novel monoclonal antibodies and vaccines for the treatment of cancer. It is used for the treatment of melanoma. SCIB1 is a plasmid DNA which encodes a human antibody molecule engineered to express a melanoma antigen called Tyrosinase-Related Protein 2 (TRP2) plus two helper T cell epitopes. The Immunobody vaccines are used in the treatment of colorectal cancer. It may also be utilised in the treatment of infectious diseases. During the fiscal year ended April 30, 2010 (fiscal 2010), the Company owned 100% interest in its subsidiary, Scancell Limited.